Italia markets closed

Mirati Therapeutics, Inc. (MRTX)

NasdaqGS - NasdaqGS Prezzo in tempo reale. Valuta in USD.
Aggiungi a portafoglio
180,20-0,05 (-0,03%)
Alla chiusura: 4:00PM EDT

Mirati Therapeutics, Inc.

9393 Towne Centre Drive
Suite 200
San Diego, CA 92121
United States
858 332 3410
http://www.mirati.com

Settore/iHealthcare
SettoreBiotechnology
Impiegati a tempo pieno111

Figure dirigenziali chiave

NomeTitoloRetribuzioneEsercitateAnno di nascita
Dr. Charles M. BaumPres, CEO & Director1,01MN/D1958
Dr. James G. ChristensenChief Scientific Officer & Exec. VP655kN/D1968
Mr. Daniel R. FagaExec. VP, COO & Principal Financial OfficerN/DN/D1980
Ms. Vickie S. ReedSr. VP of Technical Operation & Chief Accounting OfficerN/DN/D1962
Temre JohnsonDirector of Investor Relations & Corp. CommunicationsN/DN/DN/D
Ms. Reena R. DesaiVP, Gen. Counsel & Corp. Sec.N/DN/DN/D
Mr. Matthew MarxVP & Head of Drug DiscoveryN/DN/DN/D
Mr. Philip RobertsSr. VP of Technical OperationsN/DN/DN/D
Mr. Benjamin J. HickeyExec. VP & Chief Commercial OfficerN/DN/D1975
Dr. Kelly Covello Ph.D.VP & Head of Medical AffairsN/DN/DN/D
Gli importi risalgono al giorno 31 dicembre 2019 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. It is developing MRTX849, a KRAS G12C inhibitor, which is in Phase I/II clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; and sitravatinib, a spectrum-selective kinase inhibitor that is in Phase II clinical trial for the treatment of NSCL cancer, as well as a KRAS G12D inhibitor program, which is in preclinical development. The company has a collaboration and license agreement with BeiGene, Ltd. to develop, manufacture, and commercialize sitravatinib; and a clinical collaboration agreement with Novartis Pharmaceuticals Corporation. Mirati Therapeutics, Inc. was founded in 1995 and is headquartered in San Diego, California.

Governance aziendale

L'ISS Governance QualityScore di Mirati Therapeutics, Inc. al 6 ottobre 2020 è 5. I criteri di valutazione fondamentali sono revisione: 2; Consiglio di Amministrazione: 5; diritti degli azionisti: 4; retribuzione: 8.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.